GSK Takes A Deep Breath And Drops $1bn On Aiolos
The UK firm is following in AstraZeneca’s footsteps in doing a deal for an anti-TSLP antibody, though it remains some way behind its rival.
The UK firm is following in AstraZeneca’s footsteps in doing a deal for an anti-TSLP antibody, though it remains some way behind its rival.